Related Experiment Videos
[Therapy of dilated cardiomyopathy with digitalis, diuretics and vasodilators]
Insights
Diuretics and angiotensin-converting enzyme (ACE) inhibitors improve prognosis for dilated cardiomyopathy patients with sinus rhythm. Digitalis is recommended if atrial fibrillation or tachyarrhythmia develops.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Dilated cardiomyopathy (DCM) treatment primarily addresses congestive heart failure (CHF).
- Digitalis efficacy in DCM, especially with sinus rhythm, is debated.
- Diuretics and vasodilators are key for managing CHF symptoms in DCM.
Purpose:
- To evaluate current therapeutic strategies for dilated cardiomyopathy.
- To determine the role of diuretics, digitalis, and ACE inhibitors in DCM management.
- To identify optimal treatment for DCM patients with sinus rhythm versus arrhythmias.
Summary:
- Diuretics alleviate CHF by reducing preload and afterload, potentially improving DCM prognosis.
- Angiotensin II converting enzyme (ACE) inhibitors offer both arterial and venous dilation and improve CHF prognosis, addressing the renin-angiotensin system's role.
- Combined diuretic and ACE inhibitor therapy is currently the most reasonable approach for DCM patients with sinus rhythm; digitalis is indicated for arrhythmias.
Impact:
- Establishes a foundational treatment strategy for dilated cardiomyopathy.
- Highlights the prognostic benefits of ACE inhibitors and diuretics in CHF management.
- Provides guidance on digitalis use based on cardiac rhythm in DCM patients.
Abstract:
The treatment of dilated cardiomyopathy is primarily concerned with that of congestive heart failure. Digitalis is widely use in dilated cardiomyopathy but an improvement in the prognosis has not yet been demonstrated. Furthermore, the effects of digitalis in patients with sinus rhythm are debatable. If dilated cardiomyopathy induces atrial fibrillation and tachyarrhythmia, digitalis should be used. Diuretics are helpful in the treatment of congestive heart failure associated with dilated cardiomyopathy. By reducing hypervolemia and by venous dilatation, diuretics lower preload and afterload. This leads to relief of congestion and termination of the vicious cycle of congestive heart failure. Accordingly, the prognosis of dilated cardiomyopathy might be improved by diuretics. There are numerous diuretics acting differently on the renal tubules, the choice of which depends on the renal function and serum electrolyte concentrations. Reduction of preload and afterload improves congestive heart failure as has been demonstrated repeatedly. Many substances have therefore been used for arterial and venous dilation with differing results. At least for short-term periods, congestion is reduced and cardiac output increases. Especially inhibitors of angiotensin II converting enzyme are very effective since they act both in the arterial and venous systems. Additionally, inhibition of the action of angiotensin may be regarded as causal therapy since the renin-angiotensin system is the trigger for vasoconstriction and fluid retention in congestive heart failure. Unlike other substances, ACE inhibitors have been demonstrated to improve prognosis of patients with congestive heart failure. At present, combined diuretic therapy and angiotensin conversion enzyme inhibition would seem the most reasonable treatment for patients with dilated cardiomyopathy and sinus rhythm. If atrial fibrillation and tachyarrhythmia develop, additional digitalis therapy is effective.